For children and adolescents with type 1 diabetes, Fiasp could be an option to better manage their blood sugar levels.- Novo Nordisk

For children and adolescents (1 to less then 18 years old) living with type 1 diabetes, Fiasp (an ultra-fast acting formulation of insulin aspart) could be an option to better manage their blood sugar levels. New data presented at the 44th Annual Conference of the International Society for Pediatric and Adolescent Diabetes (ISPAD) showed that the study population receiving Fiasp achieved superior reductions in overall blood sugar levels (HbA1c), compared to the group on conventional insulin aspart , when both treatments were dosed at mealtime (estimated treatment difference (ETD) -0.17%). In addition, significantly lower overall post-meal blood sugar levels (1-hour after the meal) were achieved with Fiasp� compared to conventional insulin aspart.

Another group of study participants, that injected Fiasp 20 minutes after the start of the meal, achieved similar overall blood sugar levels to those taking conventional insulin aspart dosed at mealtime (non-significant ETD of 0.13% in favour of conventional insulin aspart). These results confirm the non-inferior profile of action of Fiasp when dosed 20 minutes after the start of the meal, compared with conventional insulin aspart dosed at mealtime.There were no significant differences in the overall rate of severe or blood-sugar confirmed hypoglycaemic episodes, or overall rates of other adverse events such as nausea or injection site reactions, confirming the safety profile of Fiasp in comparison to conventional insulin aspart.